论文部分内容阅读
美国普强公司于1973年11月底宣布:该公司的前列腺素F_(2α)制剂“Prostin F_(2α)”已经取得“食品药物管理处”的正式批准,在美国开始行销。这种药品经医师处方可用于后期(3～6月)流产。目前上市的是一种羊膜内注射用的制剂。另外,据该公司宣称:目前这种药品开始在过去曾经作过研究的大学医学中心及对使用技术比较熟悉的医师的单位供应。该公司与瑞典斯德哥尔摩的卡罗林斯加学院合作进行的研究表明:前列腺素及其拮抗剂对某些心血管病、胃溃疡、气喘和某些炎症可能有疗效,并可用于绝育和流产。最近,在人体内部的前列腺素合成中,发现了两种新的前列腺素中间体——前列腺素G_2和前列腺素H_2。据卡罗林斯加学院声称,这两种中间体都是桥过氧化物(Endo-Peroxides)。
The United States Puqiang company announced in late November 1973: The company’s prostaglandin F_ (2α) preparation “Prostin F_ (2α)” has obtained the “Food and Drug Administration,” the official approval of the United States began marketing. This medicine can be used by the doctor for the late (3 to 6 months) abortion. Currently on the market is an amniotic injection formulations. In addition, according to the company, the drug is currently being offered at university medical centers that have been studied in the past and by those who are more familiar with the use of technology. The company’s collaboration with Karolinska Institute in Stockholm, Sweden, shows that prostaglandins and their antagonists may be effective in certain cardiovascular diseases, gastric ulcers, asthma and certain inflammatory conditions and may be used for sterilization and miscarriage. Recently, two new prostaglandin intermediates, prostaglandin G_2 and prostaglandin H_2, have been found in human prostaglandin synthesis. According to Karolinska Institute, both of these intermediates are endo-peroxides.